Mycobacteria: Genetics of resistance and implications for treatment

Chemotherapy

Volumn 45, Issue 2, 1999, Pages 95-108

  Sander, Peter ^a   Böttger, Erik C ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NONE

Author keywords

Drug resistance; Mycobacteria

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ETHAMBUTOL; ISONIAZID; MACROLIDE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL GENETICS; MYCOBACTERIOSIS; MYCOBACTERIUM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

EID: 0033060224     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007171     Document Type: Review

References (73)

1. Fischl MA, Daikos GL, Uttamchandani RB, Poblete RB, Moreno JN, Reyes RR, Brota AM, Thompson LM, Cleary TJ, Oldham SA, Saldava MJ, Lai S: Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli. Ann Intern Med 1992;117: 184-190.
2. Busillo CP, Lessnau KD, Sanjana V, Sounakis S, Davidson M, Mullen MP, Talavera W: Multidrug resistant Mycobacterium tuberculosis in patients with human immunodeficiency virus infection. Chest 1992; 102:791-801.
3. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR: Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993;328:527-532.
4. Salomon N, Perlman DC, Friedman P, Buchstein S, Kreiswirth BN, Mildvan D: Predictions and outcome of multidrug-resistant tuberculosis. Clin Infect Dis 1995;21: 1245-1252.
5. Turett GS, Telzak EE, Torian LV, Blum S, Alland D, Weisfuss I, Fazal BA: Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis 1995;21:1238-1244.
6. Telzak EE, Sepkowitz K, Albert P, Mannheimer S, Medard F, El-Sadu W, Blum S, Gagliardi A, Salomon N, Turett G: Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995;333: 907-911.
7. Park MM, Davis AL, Schluger NW, Cohen H, Rom WN: Outcome of MDR-TB patients, 1983-1993. Prolonged survival with appropriate therapy. Am J Respir Crit Care Med 1996;153:317-324.
8. Finken M, Kirschner P, Meier A, Wrede A, Böttger EC: Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: Alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot. Mol Microbiol 1993;9: 1239-1246.
9. Heym B, Honore N, Truffot-Pernot C, Banerjee A, Schurra C, Jacobs WR, van Embden JDA, Grosset JH, Cole ST: Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: A molecular study. Lancet 1994; 344:293-298.
10. Morris SL, Rouse DA: The genetic of multiple drug resistance in Mycobacterium tuberculosis and the Mycobacterium avium complex. Res Microbiol 1996;147:68-73.
11. Zhang Y, Young DB: Molecular mechanisms of isoniazid: A drug at the front line of tuberculosis control. Trends Microbiol 1993;1:109-113.
12. Böttger EC: Resistance to drugs targeting protein synthesis in mycobacteria. Trends Microbiol 1994;2: 416-421.
13. Musser JM: Antimicrobial agent resistance in mycobacteria: Molecular genetic insights. Clin Microbiol Rev 1995;8:496-514.
14. Sander P, Meier A, Böttger EC: Ribosomal drug resistance in mycobacteria. Res Microbiol 1996;147: 59-67.
15. Zhang Y: Molecular basis of drug resistance in M. tuberculosis. J Med Microbiol 1996;44:5-7.
16. Blanchard JS: Molecular mechanisms of drug resistance in Mycobacterium tuberculosis. Annu Rev Biochem 1996;65:215-239.
17. Bernstein J, Lott WA, Steinberg BA, Yale HL: Chemotherapy of experimental tuberculosis. Isonicotinic acid hydrazide (nydrazid) and related compounds. Am Rev Tuberc 1952;65:357-364.
18. Sacchettini JC, Blanchard JS: The structure and function of the isoniazid target in M. tuberculosis. Res Microbiol 1996;147:36-43.
19. Zhang Y, Young D: Strain variation in the katG region of Mycobacterium tuberculosis. Mol Microbiol 1994;14:301-308.
20. Heym B, Zhang Y, Poulet S, Young D, Cole ST: Characterization of the katG gene encoding a catalase-peroxidase required for the isoniazid susceptibility of Mycobacterium tuberculosis. J Bacteriol 1993;175: 4255-4259.
21. Zhang Y, Heym B, Allen B, Young D, Cole S: The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992;358:591-593.
22. Zhang Y, Garbe T, Young D: Transformation with katG restores isoniazid-sensitivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentrations. Mol Microbiol 1994;8:521-524.
23. Pretorius GS, van Helden PD, Sirgel F, Eisenach KD, Victor TC: Mutations in katG sequences in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis are rare. Antimicrob Agents Chemother 1995; 39:2276-2281.
24. Jaber M, Rattan A, Kumar R: Presence of katG gene in resistant Mycobacterium tuberculosis. J Clin Pathol 1996;9:945-947.
25. Cockerill FR, Uhl JR, Temesgen Z, Zhang Y, Stockman L, Roberts GD, Williams DL, Kline BC: Rapid identification of a point mutation of the Mycobacterium tuberculosis catalase peroxidase (katG) gene associated with isoniazid resistance. J Infect Dis 1995;171:1240-1245.
26. Rouse DA, Li Z, Bai GH, Morris SL: Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995;39:2472-2477.
27. Rouse DA, DeVito JA, Li Z, Byer H, Morris SL: Site directed mutagenesis of the katG gene of Mycobacterium tuberculosis: Effects on catalase-peroxidase activities and isoniazid resistance. Mol Microbiol 1996;22:583-592.
28. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, Collins D, de Lisle G, Jacobs WR: inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994;263:227-230.
29. Kapur V, Li LL, Hamrick MR, Plikaytis BB, Shinnick TM, Telenti A, Jacobs WR, Banerjee A, Cole S, Yuen KY, Klarridge JE, Kreiswirth BN, Musser JM: Rapid Mycobacterium species assignment and unambiguous identification of mutations associated with antibiotic resistance in Mycobacterium tuberculosis by automated DNA sequencing. Arch Pathol Lab Med 1995;119:131-138.
30. Telenti A, Honoré N, Bernasconi C, March J, Ortega A, Heym B, Takiff HE, Cole ST: Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: A blind study at reference laboratory level. J Clin Microbiol 1997;35: 719-723.
31. Dhandayuthapani S, Zhang Y, Mudd MH, Deretic V: Oxidative stress response and its role in sensitivity to isoniazid in mycobacteria: Characterization and inducibility of ahpC by peroxides in Mycobacterium smegmatis and lack of expression in M. aurum and M. tuberculosis. J Bacteriol 1996;178:3641-3649.
32. Wilson TM, Collins DM: ahpC, a gene involved in isoniazid resistance of the Mycobacterium tuberculosis complex. Mol Microbiol 1996;19: 1025-1034.
33. Deretic V, Pagan-Ramos E, Zhang Y, Dhandayuthapani S, Via LE: The extreme sensitivity of Mycobacterium tuberculosis to the front-line antituberculosis drug isoniazid. Nat Biotechnol 1996;14:1557-1561.
34. Zhang Y, Dhandayuthapani S, Deretic V: Molecular basis for the exquisite sensitivity of Mycobacterium tuberculosis to isoniazid. Proc Natl Acad Sci USA 1996;93:13212-13216.
35. Deretic V, Philipp W, Dhandayuthapani S, Mudd MH, Curcic R, Garbe T, Heym B, Via LE, Cole ST: Mycobacterium tuberculosis is a natural mutant with an inactivated oxidative-stress regulatory gene: Implications for sensitivity to isoniazid. Mol Microbiol 1995;17:889-900.
36. Heym B, Stavropoulos E, Honore N, Domeneck P, Saint-Joanis B, Wilson TM, Collins DM, Colston MJ, Cole ST: Effects of overexpression of the alkyl hydroperoxide reductase AhpC on the virulence and isoniazid resistance of Mycobacterium tuberculosis. Infect Immun 1997;65: 1395-1401.
37. Heifets L, Lindholm-Levy P: Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis 1992;145: 1223-1225.
38. Scorpio A, Zhang Y: Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 1996;2:1-6.
39. Scorpio A, Lindholm-Levy P, Heifets L, Gilman R, Siddiqi S, Cynamon M, Zhang Y: Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997;41:540-543.
40. Sreevatsan S, Pan X, Zhang Y, Kreiswirth BN, Musser JM: Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob Agents Chemother 1997;41:636-640.
41. Levin ME, Hatfull GF: Mycobacterium smegmatis RNA polymerase: DNA supercoiling, action of rifampicin and mechanism of rifampicin resistance. Mol Microbiol 1993;8: 277-285.
42. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston JJ, Matter L, Schopfer K, Bodmer T: Detection of rifampicin-resistant mutations in Mycobacterium tuberculosis. Lancet 1993;341:647-650.
43. Miller LP, Crawford JT, Shinnick TM: The rpoB gene of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994;38:805-811.
44. Bodmer T, Zürcher G, Imboden P, Telenti A: Mutation position and type of substitution in the β-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant M. tuberculosis. J Antimicrob Chemother 1995;35: 345-348.
45. Dabbs ER, Yazawa K, Mikami Y, Morisaki N, Iwasaki S, Furihata K: Ribosylation by mycobacterial strains as a new mechanism of rifampin inactivation. Antimicrob Agents Chemother 1995;39:1007-1009.
46. Telenti A, Philipp WJ, Sreevatsan S, Bernasconi C, Stockbauer KE, Wieles B, Musser JM, Jacobs WR: The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat Med 1997;3:567-570.
47. Belanger AE, Besra GS, Ford ME, Mikosuva K, Belisle T, Brennan PJ, Inamine JM: The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci USA 1996;93:11919-11924.
48. Sreevatsan S, Stockbauer KE, Pan X, Kreiswirth BN, Moghazeh SL, Jacobs WR, Telenti A, Musser JM: Ethambutol resistance in Mycobacterium tuberculosis: Critical role of embB mutations. Antimicrob Agents Chemother 1997;41:1677-1681.
49. Meier A, Kirschner P, Bange FC, Vogel U, Böttger EC: Genetic alterations in streptomycin-resistant Mycobacterium tuberculosis: mapping of mutations conferring resistance. Antimicrob Agents Chemother 1994;38:228-233.
50. Honore N, Cole ST: Streptomycin resistance in mycobacteria. Antimicrob Agents Chemother 1994;38: 238-242.
51. Sreevatsan S, Pan X, Stockbauer KE, Williams DL, Kreis-Wirth BN, Musser JM: Characterization of rpsL and rrs mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from diverse geographic localities. Antimicrob Agents Chemother 1996;40:1024-1026.
52. Moazed D, Noller HF: Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature 1987; 327:389-394.
53. Meier A, Sander P, Schaper KJ, Scholz M, Böttger EC: Correlation of molecular resistance mechanisms and phenotypic resistance level in streptomycin resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996;40:2452-2454.
54. Hoffner SE, Svenson SB, Källenius G: Synergistic effects of antimycobacterial drugs on Mycobacterium avium complex determined radiometrically in liquid medium. Eur J Clin Microbiol Infect Dis 1987;6: 530-535.
55. Dautzenberg B, Truffot C, Legris S, Meyohas MC, Berlie HC, Mercat A, Chevret S, Grosset J: Activity of clarithromycin against Mycobacterium avium infections in patients with the acquired immune deficiency syndrome. Am Rev Respir Dis 1991;144:564-569.
56. Brown BA, Wallace RJ, Onyi GO: Activities of clarithromycin against eight slowly growing species of non-tuberculous mycobacteria determined by using a broth microdilution MIC system. Antimicrob Agents Chemother 1992;36:1987-1990.
57. Brown BA, Wallace RJ, Onyi GO, de Rosas V, Wallace RJ: Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum. Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother 1992; 36:180-184.
58. Dautzenberg B, Saint Marc T, Meyohas MC, Eliaszewitch M, Haniez F, Rogues AM, DeWit S, Cotte L, Chauvin JP, Grosset J: Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome. Arch Intern Med 1993;153:368-372.
59. Wallace RJ, Brown BA, Griffith DE, Girard WM, Murphy DT, Onyi GO, Steingrube VA, Mazurck GH: Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med 1994;149: 1335-1341.
60. Tebas P, Sultan F, Wallace RJ, Fraser V: Rapid development of resistance to clarithromycin following monotherapy for disseminated Mycobacterium chelonae infection in a heart transplant patient. Clin Infect Chemother 1995;20:443-444.
61. Weisblum B: Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother 1995;39:577-585.
62. Meier A, Kirschner P, Springer B, Steingrube VA, Brown BA, Wallace RJ, Bottger EC: Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. Antimicrob Agents Chemother 1994;38:381-384.
63. Wallace RJ, Meier A, Brown BA, Zhang Y, Sander P, Onyi GO, Böttger EC: Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother 1996;40:1676-1681.
64. Meier A, Heifets L, Wallace RJ, Zhang Y, Brown PA, Sander P, Böttger EC: Molecular mechanisms of clarithromycin resistance in Mycobacterium avium; observation of multiple 23S r-DNA mutations in a clonal population. J Infect Dis 1996; 174:354-360.
65. Sander P, Prammananan T, Frischkorn K, Meier A, Böttger EC: The role of ribosomal rRNAs in macrolide resistance. Mol Microbiol 1997; 26:469-480.
66. Davies J, Wright GD: Bacterial resistance to aminoglycoside antibiotics. Trends Microbiol 1997;5:234-240.
67. Ainsa JA, Perez E, Pelicic V, Berthet FX, Gicquel B, Martin C: Aminoglycosie 2′-N-acetyltransferase genes are universally present in mycobacteria: Characterization of the aac(2′)-Ic gene from Mycobacterium tuberculosis and the aac(2′)-Id gene from Mycobacterium smegmatis. Mol Microbiol 1997;24:431-441.
68. Sander P, Prammananan T, Böttger EC: Introducing mutations into a chromosomal rRNA gene using a genetically modified eubacterial host with a single rRNA operon. Mol Microbiol 1996;22:841-848.
69. Prammananan T, Sander P, Brown BA, Frischkorn K, Onyi GO, Zhang Y, Böttger EC, Wallace RJ: A single 16S ribosomal RNA substitution is responsible for amikacin and other 2-deoxystreptamine aminoglycoside resistance in Mycobacterium abscessus and Mycobacterium chelonae. J Infect Dis 1998;177:1573-1581.
70. Nightingale SD, Cameron DW, Gordin FM, Sullam PM, Cohn DL, Chaisson RE: Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993; 329:828-833.
71. Havlir DV, Dube MP, Sattler FR, Forthal DN, Kemper CA, Dunne MW: Propylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996;335:392-398.
72. Pierce M, Crampton S, Henry D, Heifets L, La Marca A, Montecalvo M: A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996;335:384-391.
73. Böttger EC, Böttger O, Stichnoth DO: Prophylaxis of mycobacterial infection and acquired drug resistance. J Antimicrob Chemother 1997;40:145-146.